|
1-Jan-2006
|
351
|
Newly diagnosed patients with MM treated with 2 cycles of high-dose melphalan and autologous stem cell transplantation [8].
|
Shaughnessy JD Jr, Barlogie B. “Using genomics to identify high-risk Myeloma after autologous stem cell transplantation”. Biol Blood Marrow Transplant 2006; 12 (1 Suppl 1):77–80.
|
|
25-May-2006
|
414
|
Newly diagnosed patients treated with high-dose melphalan-based tandem transplants [9].
|
Zhan et al. “The molecular classification of multiple myeloma”. Blood 2006; 108(6):2020–2028.
|
|
14-Nov-2006
|
532
|
Newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols [6].
|
Shaughnessy et al. “A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1”. Blood 2007; 109:2276–84.
|
|
9-May-2007
|
220
|
Newly diagnosed patients treated with TT2 [10].
|
Shaughnessy et al. “Testing standard and genetic parameters in 220 patients with multiple Myeloma with complete data sets: superiority of molecular genetics”. Br J Haematol 2007; 137:530–536.
|
|
22-Jun-2007
|
303
|
Newly diagnosed patients with myeloma treated with Total therapy 3 (incorporating bortezomib into a melphalan-based tandem transplant regimen) [11].
|
Barlogie et al. “Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3”. Br J Haemotol 2007; 138:176-185
|
|
7-Sep-2007
|
71
|
Newly diagnosed multiple myeloma patients treated with high-dose melphalan and stem cell transplant [12].
|
Chng et al. “Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature”. Leukemia 2008; 22:459–61.
|
|
1-Dec-2007
|
326
|
Newly diagnosed patients with myeloma received a tandem autotransplant regimen [13].
|
Haessler et al. “Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling”. Clin Cancer Res. 2007; 13(23):7073-7079
|
|
15-Jan-2008
|
156
|
Relapsed myeloma patients enrolled in the APEX phase 3 clinical trial that compared single-agent bortezomib (B) to high-dose dexamethasone (HD) [14].
|
Zhan et al. “High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.” Blood 2008; 111(2):968–969.
|
|
30-Jun-2008
|
250
|
Two hundred fifty patients with myeloma at diagnosis with at least 500,000 available bone marrow CD138+ plasma cells [15].
|
Decaux etl al. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome JCO October 10, 2008:4798–4805;
|
|
29-Mar-2009
|
290
|
Untreated myeloma patients with cytogenetic abnormalities (CA) present in randomly sampled (RS) or focal lesion (FL) bone marrow sites [16].
|
Zhou et al. “Cytogenetic abnormalities in multiple myeloma: poor prognosis is linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile”. Br J Haematol 2009; 145(5):637-641
|
|
25-Jun-2009
|
120
|
Myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2 [7].
|
Nair et al. “Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival”. Blood 2009; 113:6572–5.
|
|
14-Mar-2010
|
258
|
Newly diagnosed patients with multiple myeloma entered into the MRC Myeloma IX study [17].
|
Dickens et al. Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clin Cancer Res March 15, 2010 16:1856–1864;
|
|
12-Apr-2010
|
52
|
Patients newly diagnosed with MM [18].
|
Zhou et al. “High-risk myeloma is associated with global elevation of MiRNAs and overexpression of EIF2C2/AGO2”. Proc Natl Acad Sci USA 2010; 107(17): 7904-790
|
|
30-Sep-2010
|
757
|
Previously untreated patients undergoing high-dose chemotherapy [19].
|
Hose et al. “Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma”. Haematologica 2011; 96(1):87–95.
|
|
20-Aug-2010
|
275
|
Newly diagnosed patients with symptomatic or progressive myeloma [20].
|
van Rhee et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010 116:1220–1227;
|
|
7-Oct-2010
|
320
|
Newly diagnosed patients with MM (Dutch-Belgian Cooperative Trial Group for Hemato-Oncology [21].
|
Broyl et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010 116:2543–2553;
|
|
22-Aug-2011
|
45
|
Patients with myeloma receiving initial therapy with lenalidomide and dexamethasone [22].
|
Kumar et al. “Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone”. Blood 2011; 118(16): 4359–4362.
|
